COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

October 25, 2024
Resource Spotlight: The National Cancer Institute's Proteomic Data Commons

Large-scale datasets generated via high-throughput sequencing and multi-omics technologies are shaping how researchers uncover features of cancer biology. The National Cancer Institute's (NCI) Proteomic Data Commons (PDC), a component of the Cancer Research...
September 30, 2024
Boosting Throughput and Sensitivity in Single-Cell Proteomics by Leveraging Automated Workflows

Single-cell proteomics (SCP) is enabling researchers to understand cancer progression, immune response, developmental pathways, and more all at the cellular level. Historically, SCP has represented a considerable challenge for researchers due to low amounts of proteins within a single cell and the,...
September 13, 2024
Proteomic Data Commons Now Supports Metabolomics and Lipidomics Data

The National Cancer Institute's Proteomic Data Commons (PDC) launched in 2020, part of the National Cancer Institute's Cancer Research Data Commons (CRDC) data ecosystem, is the largest public repository of comprehensive tumor proteomic datasets, housing diverse data types such as proteome,...
August 21, 2024
IO-3 Assay Panel Offers Insights Into Immunotherapy Response

Cancer immunotherapies hold promise for inducing durable responses across cancer types, yet their effectiveness varies significantly among patients. In an effort to deepen our understanding of the mechanisms underlying response and resistance to immunotherapy, CPTAC researchers from the Fred...
August 5, 2024
Progress in Proteomics: Fernanda Martins Rodrigues, Ph.D.

The following is the sixth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss bioinformatics, proteogenomics, and research ethics with Fernanda Martins Rodrigues, PhD, a post-doctoral research...
July 16, 2024
Illuminating Key Signaling Pathways and Tumor Evolution in High-Grade Glioma

Despite improvements in detection and therapy, the prognosis for high-grade glioma (HGG) remains poor. Prior research has studied disease progression in HGG, but our understanding of how and why the disease recurs so often (>90% of patients within two years for the most aggressive HGG) remains...
June 26, 2024
Pan-Cancer Analysis Identifies Promising Therapeutic Targets

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has performed proteogenomic characterization for over 1,000 primary tumors spanning 10 cancer types: breast invasive carcinoma (BRCA), clear cell renal cell carcinoma (CCRCC), colon adenocarcinoma (COAD), glioblastoma (GBM), head and neck...
June 3, 2024
Unveiling Glycoproteins with Tung-Shing Mamie Lih, Ph.D.

The following is the fifth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of glycoproteomics research with Tung-Shing Mamie Lih, PhD, an associate researcher at Johns Hopkins...
May 7, 2024
Characterizing the Molecular Landscape of Rare Renal Cell Carcinomas

In a recent study aiming to address knowledge gaps in non-clear cell renal cell carcinoma (non-ccRCC), researchers from the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted an integrated multi-omic analysis of 48 non-ccRCC cases along with a previously...
April 25, 2024
Driving Change in Cancer Research: Insights from Yifat Geffen

The following is the fourth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteogenomics research with Yifat Geffen, PhD, a postdoctoral researcher at the Broad Institute of MIT...
April 4, 2024
Characterizing the Evolution of Glioblastoma

Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have...
March 29, 2024
Presenting our 2024 CPTAC Meritorious Posters

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium...
March 20, 2024
Proteomics in Focus: Insights from Dr. Nicole Tignor

The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at...
February 23, 2024
Proteogenomic Characterization of Small Cell Lung Cancer: A Pathway to Personalized Medicine

Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.
February 14, 2024
Deciphering the Tumor Microenvironment: A Proteogenomic Pan-Cancer Analysis

The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...
January 22, 2024
Advancing Personalized Treatment Strategies for Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.
January 8, 2024
Excellence in Proteomics Research: A Conversation with Jeffrey Whiteaker

The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...
more

View all News and Announcements